Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q4 2022 Earnings Call Transcript

The first 4 cohorts, we all completed. We completed each one of them in 2 to 3 months. And in terms of how many cohorts we’re going to have to go, I do not have a crystal ball. I can’t tell you. Do I — in my gut, do I think we’re probably getting close? Yes, I do. The sixth cohort is at 240 milligrams. Will that be as high as we need to go? Or do we need to go to 280? It won’t — that decision won’t just be driven by the AE profile. It will also be driven by the PD data, the pharmacodynamic data, because we’re going to look for a dose that maybe isn’t the MTD, or maximum tolerated dose, but look for a dose where we see maximum biologic effectiveness, too. So it’s just hard to say.

Operator: I’m showing no further questions in queue. At this time, I’d like to turn the call back over to the speakers for closing remarks.

Steven Fruchtman: Thank you all again for joining today to hear about our recent progress and outlook for the rest of the year. We are obviously excited to be nearing several important clinical milestones and appreciate your continued interest in the important, if not crucial, work we are doing. Thanks, again, and enjoy your evening and look forward to seeing many of you going forward. Thank you.

Operator: Ladies and gentlemen, thank you for your participation on today’s conference call. This concludes today’s event. You may now disconnect.